North Yorkshire & York Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on the 4th August 2021

Classification of products:

G **Green drug** - Can be initiated and prescribed in all care settings O- Second line / alternative green drug

ASR **Amber Specialist Recommendation drug -** Can be recommended by a specialist for initiation in primary care

ASI **Amber Specialist Initiation drug** – Initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.

ASC **Amber Shared Care drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care

R **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as "hospital only" drugs

BLACK **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within North Yorkshire & York.

GREY **Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in North Yorkshire & York.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
TA694: Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia			✓	Decision deferred to confirm with NICE and local lipid specialists in place therapy in those whose dose of statin cannot be increased to usually max recommended dose.
2) New Requests				
Nil this month				
3) New formulations & extensions to use				
Nil this month				
5) Products considered by NICE				
TA712: Enzalutamide for treating hormone-sensitive metastatic prostate cancer	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA713: Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
TA714: Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner – NICE TA was terminated.
TA715: Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed	✓ R			The formulary will reflect the TAG – CCGs are the responsible commissioner.
TA716: Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA717: Duvelisib for treating relapsed follicular lymphoma after 2 or more systemic therapies (terminated appraisal)				The formulary will reflect the TAG – NHS England is the responsible commissioner – NICE TA was terminated.
TA718: Ixekizumab for treating axial spondyloarthritis	✓ R			The formulary will reflect the TAG – CCGs are the responsible commissioner.
TA719: Secukinumab for treating non-radiographic axial spondyloarthritis	✓ R			The formulary will reflect the TAG – CCGs are the responsible commissioner.
6) Appeals against earlier decisions by the APC				
None				
7) Miscellaneous formulary decisions by the APC				
Estring 7.5micrograms/24 hours and Ring Pessaries	✓ G			Approved for addition to the formulary in line with VoY CCG Referral Support Service GY17 Prolapse document.

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Indapamide modified release	✓ G			Approved as an alternative option to indapamide immediate release where hypokalaemia is an issue with the immediate release formulation. Indapamide immediate release and indapamide modified release (MR) are both once daily preparations. There appears to be no difference in anti-hypertensive efficacy between the two formulations but the modified release preparation has a lower incidence of hypokalemia. Immediate release formulation remains more cost-effective than modified release.
Lacri-lube eye ointment – to delete from formulary as discontinued	✓			To delete from formulary as discontinued. Alternatives: Xailin Night eye ointment (contains white soft paraffin, white mineral oil and lanolin alcohols) HYLO NIGHT (formerly VitA-POS) (contains retinol palmitate (vitamin A), liquid paraffin, light liquid paraffin, wool fat and white soft vaseline)
Chloramphenicol eye drops	✓			Approved removing sentence that Chloramphenicol Eye drops contra-indicated in under 2 year olds from Harrogate formulary as per MHRA DSU July 2021. Given the toxicological data and the calculation of daily exposure from a typical dosing regimen, it has been concluded by the MHRA that the benefit-risk balance of chloramphenicol eye drops containing boron or boric acid remains positive for children aged 0 to 2 years. The product information for affected chloramphenicol products will be updated shortly to reflect the revised advice that these products can be safely administered to children aged 0 to 2 years. MHRA have requested the removal of restrictions and associated warnings about boron exposure in children aged 0 to 2 years from the product information (Summary of Product Characteristics and Patient Information Leaflets) for UK chloramphenicol eye drop products.

The following guidelines were presented to and approved at the August 2021 meeting of the APC:

- Dapagliflozin for heart failure – final guideline
- Biologics pathway for moderate rheumatoid arthritis: updated version approved. Includes Adalimumab, etanercept and infliximab as per NICE TA
- Biologics pathway for Axial Spondyloarthritis and non-radiographic axial spondyloarthritis (updated): updated version approved. Includes secukinumab and Ixekizumab as per NICE TA

The following shared care guidelines were presented to and approved at the August 2021 meeting of the APC:

- Nil this month

Other documents presented to and approved at the July 2021 meeting of the APC:

- North Yorkshire & York APC Terms of Reference
- North Yorkshire & York APC Formulary Application Form
- North Yorkshire & York APC Formulary RAG Definitions Guideline